Alterations in gut hormones after laparoscopic sleeve gastrectomy: A prospective clinical and laboratory investigational study

Annals of Surgery

Volumn 257, Issue 4, 2013, Pages 647-654

  Dimitriadis, Efstathios ^a   Daskalakis, Markos ^a   Kampa, Marilena ^a   Peppe, Anastasia ^a   Papadakis, John A ^b   Melissas, John ^a  

^a UNIVERSITY OF CRETE   (Greece)

^b UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

amylin; glucagon like peptide 1; pancreatic polypeptide; peptide YY; sleeve gastrectomy

Indexed keywords

ADIPOCYTOKINE; AMYLIN; GASTROINTESTINAL HORMONE; GHRELIN; GLUCAGON LIKE PEPTIDE 1; LEPTIN; PEPTIDE YY;

ADULT; ARTICLE; BARIATRIC SURGERY; BODY MASS; CLINICAL ARTICLE; FEMALE; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; HUMAN; LAPAROSCOPIC SURGERY; MALE; MORBID OBESITY; POSTOPERATIVE PERIOD; POSTPRANDIAL STATE; PRIORITY JOURNAL; SLEEVE GASTRECTOMY; WEIGHT REDUCTION;

ADULT; BARIATRIC SURGERY; BODY MASS INDEX; FASTING; FEMALE; GASTRECTOMY; GASTROINTESTINAL HORMONES; HUMANS; LAPAROSCOPY; MALE; MIDDLE AGED; OBESITY, MORBID; POSTPRANDIAL PERIOD;

EID: 84875208789     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e31826e1846     Document Type: Article

References (61)

1. Regan JP, Inabnet WB, Gagner M, et al. Early experience with two-stage laparoscopic Roux-en-Y gastric bypass as an alternative in the super-super obese patient. Obes Surg. 2003;13:861-864.
2. Almogy G, Crookes PF, Anthone GJ. Longitudinal gastrectomy as a treatment for the high-risk super-obese patient. Obes Surg. 2004;14:492-497.
3. Baltasar A, Serra C, Perez N, et al. Laparoscopic sleeve gastrectomy: a multipurpose bariatric operation. Obes Surg. 2005;15:1124-1128.
4. Deitel M, Crosby RD, Gagner M. The first international consensus summit for sleeve gastrectomy (SG), New York City, October 25-27, 2007. Obes Surg. 2008;18:487-496.
5. Gagner M, Deitel M, Kalberer TL, et al. The second international consensus summit for sleeve gastrectomy, March 19-21, 2009. Surg Obes Relat Dis. 2009;5:476-485.
6. Daskalakis M, Weiner RA. Sleeve gastrectomy as a single-stage bariatric operation: indications and limitations. Obes Facts. 2009;2:8-10.
7. Melissas J,Koukouraki S,Askoxylakis J, et al. Sleeve gastrectomy: a restrictive procedure? Obes Surg. 2007;17:57-62.
8. Melissas J, Daskalakis M, Koukouraki S, et al. Sleeve gastrectomy - a "food limiting" operation. Obes Surg. 2008;18:1251-1256.
9. Karamanakos SN, Vagenas K, Kalfarentzos F, et al. Weight loss, appetite suppression, and changes in fasting and postprandial ghrelin and peptide-YY levels after Roux-en-Y gastric bypass and sleeve gastrectomy: a prospective, double blind study. Ann Surg. 2008;247:401-407.
10. Schwartz MW, Morton GJ. Obesity: keeping hunger at bay. Nature. 2002;418:595-597.
11. Deitel M, Gawdat K, Melissas J. Reporting weight loss 2007. Obes Surg. 2007;17:565-568.
12. Date Y,KojimaM,Hosoda H, et al.Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. Endocrinology. 2000;141:4255-4261.
13. Vincent RP, le Roux CW. Changes in gut hormones after bariatric surgery. Clin Endocrinol (Oxf). 2008;69:173-179.
14. Camilleri M, Papathanasopoulos A, Odunsi ST. Actions and therapeutic pathways of ghrelin for gastrointestinal disorders. Nat Rev Gastroenterol Hepatol. 2009;6:343-352.
15. Cummings DE, Weigle DS, Frayo RS, et al. Plasma ghrelin levels after dietinduced weight loss or gastric bypass surgery. N Engl J Med. 2002;346:1623-1630.
16. Pournaras DJ, le Roux CW. Ghrelin and metabolic surgery. Int J Pept. 2010;pii:217267.
17. Garcia-Fuentes E, Garrido-Sanchez L, Garcia-Almeida JM, et al. Different effect of laparoscopic Roux-en-Y gastric bypass and open biliopancreatic diversion of Scopinaro on serumPYY and ghrelin levels. Obes Surg. 2008;18:1424-1429.
18. Batterham RL, le Roux CW, Cohen MA, et al. Pancreatic polypeptide reduces appetite and food intake in humans. J Clin Endocrinol Metab. 2003;88:3989-3992.
19. Track NS, McLeod RS, Mee AV. Human pancreatic polypeptide: studies of fasting and postprandial plasma concentrations. Can J Physiol Pharmacol. 1980;58:1484-1489.
20. Wisen O, Bjorvell H, Cantor P, et al. Plasma concentrations of regulatory peptides in obesity following modified sham feeding (MSF) and a liquid test meal. Regul Pept. 1992;39:43-54.
21. Glaser B, Zoghlin G, Pienta K, et al. Pancreatic polypeptide response to secretin in obesity: effects of glucose intolerance. Horm Metab Res. 1988;20:288-292.
22. Adrian TE, Ferri GL, Bacarese-Hamilton AJ, et al. Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology. 1985;89:1070-1077.
23. Batterham RL, Cohen MA, Ellis SM, et al. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med. 2003;349:941-948.
24. Alvarez BartoloḿeM, Borque M, Martinez-Sarmiento J, et al. Peptide YY secretion inmorbidly obese patients before and after vertical banded gastroplasty. Obes Surg. 2002;12:324-327.
25. le Roux CW, Welbourn R, Werling M, et al. Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. Ann Surg. 2007;246:780-785.
26. Oesch S, Ruegg C, Fischer B, et al. Effect of gastric distension prior to eating on food intake and feelings of satiety in humans. Physiol Behav. 2006;87:903-910.
27. Ballantyne GH. Peptide YY(1-36) and peptide YY(3-36): Part I. Distribution, release and actions. Obes Surg. 2006;16:651-658.
28. Cummings DE, Overduin J. Gastrointestinal regulation of food intake. J Clin Invest. 2007;117:13-23.
29. Suzuki K, Simpson KA, Minnion JS, et al. The role of gut hormones and the hypothalamus in appetite regulation. Endocr J. 2010;57:359-372.
30. Baggio LL, DruckerDJ. Biology of incretins: GLP-1 and GIP. Gastrenterology. 2007;132:2131-2157.
31. Holst JJ. The physiology of glucagon-like peptide. Physiol Rev. 2007;87:1409-1439.
32. Schirra J, Katschinski M, Weidmann C, et al. Gastric emptying and release of incretin hormones after glucose ingestion in humans. J Clin Invest. 1996;97:92-103.
33. le Roux CW, Aylwin SJ, Batterham RL, et al. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg. 2006;243:108-114.
34. Young A. Tissue expression and secretion of amylin. Adv Pharmacol. 2005;52:19-45.
35. Chapman I, Parker B,Doran S, et al. Low-dose pramlintide reduced food intake and meal duration in healthy, normal-weight subjects. Obesity (Silver Spring). 2007;15:1179-1186.
36. Reda TK, Geliebter A, Pi-Sunyer FX. Amylin, food intake, and obesity. Obes Res. 2002;10:1087-1091.
37. Reinehr T, de Sousa G, Niklowitz P, et al. Amylin and its relation to insulin and lipids in obese children before and after weight loss. Obesity (Silver Spring). 2007;15:2006-2011.
38. Koda JE, Fineman M, Rink TJ, et al. Amylin concentrations and glucose control. Lancet. 1992;339:1179-1180.
39. Chapman I, Parker B, Doran S, et al. Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes. Diabetologia. 2005;48:838-848.
40. Roth JD, Roland BL, Cole RL, et al. Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies. Proc Natl Acad Sci USA. 2008;105:7257-7262.
41. Moon HS, Chamberland JP, Diakopoulos KN, et al. Leptin and amylin act in an additive manner to activate overlapping signaling pathways in peripheral tissues: in vitro and ex vivo studies in humans. Diabetes Care. 2011;34:132-138.
42. Shintani M, Ogawa Y, Ebihara K, et al. Ghrelin, an endogenous growth hormone secretagogue, is a novel orexigenic peptide that antagonizes leptin action through the activation of hypothalamic neuropeptide Y/Y1 receptor pathway. Diabetes. 2001;50:227-232.
43. AniniY, Brubaker PL. Role of leptin in the regulation of glucagon-like peptide- 1 secretion. Diabetes. 2003;52:252-259.
44. Maffei M, Halaas J, Ravussin E, et al. Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat Med. 1995;1:1155-1161.
45. Considine RV, Sinha MK, Heiman ML, et al. Serum immunoreactiveleptin concentrations in normal-weight and obese humans. N Engl J Med. 1996;334:292-295.
46. Zimmet P, Boyko EJ, Collier GR, et al. Etiology of the metabolic syndrome: potential role of insulin resistance, leptin resistance, and other players. Ann N Y Acad Sci. 1999;892:25-44.
47. Korbonits M, Trainer PJ, Little JA, et al. Leptin levels do not change acutely with food administration in normal or obese subjects, but are negatively correlated with pituitary-adrenal activity. Clin Endocrinol (Oxf). 1997;46:751-757.
48. Papailiou J, Albanopoulos K, Toutouzas KG, et al. Morbid obesity and sleeve gastrectomy: how does it work? Obes Surg. 2010;20:1448-1455.
49. Gill RS, Birch DW, Shi X, et al. Sleeve gastrectomy and type 2 diabetes mellitus: a systematic review. Surg Obes Relat Dis. 2010;6:707-713.
50. Vidal J, Ibarzabal A, Romero F, et al. Type 2 diabetesmellitus and themetabolic syndrome following sleeve gastrectomy in severely obese subjects. Obes Surg. 2008;18:1077-1082.
51. Rizzello M, Abbatini F, Casella G, et al. Early postoperative insulin-resistance changes after sleeve gastrectomy. Obes Surg. 2010;20:50-55.
52. Woelnerhanssen B, Peterli R, Steinert RE, et al. Effects of postbariatric surgery weight loss on adipokines and metabolic parameters: comparison of laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy - a prospective randomized trial. Surg Obes Relat Dis. 2011;7:561-568.
53. Valderas JP, Irribarra V, Rubio L, et al. Effects of sleeve gastrectomy and medical treatment for obesity on glucagon-like peptide 1 levels and glucose homeostasis in non-diabetic subjects. Obes Surg. 2011;21:902-909.
54. PeterliR,WolnerhanssenB, Peters T, et al. Improvement in glucose metabolism after bariatric surgery: comparison of laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy: a prospective randomized trial. Ann Surg. 2009;250:234-241.
55. Valderas JP, Irribarra V, Boza C, et al. Medical and surgical treatments for obesity have opposite effects on peptide YY and appetite: a prospective study controlled for weight loss. J Clin Endocrinol Metab. 2010;95:1069-1075.
56. Braghetto I, Davanzo C, Korn O, et al. Scintigraphic evaluation of gastric emptying in obese patients submitted to sleeve gastrectomy compared to normal subjects. Obes Surg. 2009;19:1515-1521.
57. Shah S, Shah P, Todkar J, et al. Prospective controlled study of effect of laparoscopic sleeve gastrectomy on small bowel transit time and gastric emptying half-time in morbidly obese patients with type 2 diabetes mellitus. Surg Obes Relat Dis. 2010;6:152-157.
58. Baumann T, Kuesters S, Grueneberger J, et al. Time-resolved MRI after ingestion of liquids revealsmotility changes after laparoscopic sleeve gastrectomy - preliminary results. Obes Surg. 2011;21:95-101.
59. Murphy KG, Bloom SR. Gut hormones and the regulation of energy homeostasis. Nature. 2006;444:854-859.
60. Wang PY, Caspi L, Lam CK, et al. Upper intestinal lipids trigger a gut-brainliver axis to regulate glucose production. Nature. 2008;452:1012-1016.
61. Mithieux G. A novel function of intestinal gluconeogenesis: central signaling in glucose and energy homeostasis. Nutrition. 2009;25:881-884.